Sonnet BioTherapeutics Holdings

Founded in Princeton, New Jersey, Sonnet BioTherapeutics Holdings is a clinical-stage biotechnology company with a core mission to revolutionize cancer treatment. The company leverages its proprietary FHAB™ (Fully Human Albumin Binding) technology to develop innovative, targeted biologic drugs that feature enhanced single- or bi-specific mechanisms. Sonnet BioTherapeutics focuses on creating immune therapeutics that directly combat cancer, aiming to improve patient outcomes through advanced biologic solutions.

Notable figures affiliated with Sonnet BioTherapeutics include key scientists and industry experts who contribute to the company's groundbreaking research and development efforts. The company has attracted significant investment from venture capital firms and strategic partners, underscoring confidence in its technology and vision. Among its key achievements, Sonnet has successfully advanced several drug candidates into clinical trials, demonstrating the potential of its FHAB platform. Overall, Sonnet BioTherapeutics is making a substantial impact in the field of oncology by pioneering next-generation immune therapeutics.